Sponsor content
216 result(s) found, displaying 31 to 40
-
Australian public assessment report (AusPar)Hemgenix (etranacogene dezaparvovec), a gene therapy, has been approved for the treatment of haemophilia B (congenital factor IX deficiency) in adults.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Hong Kong Aleviate Human Coagulation Factor VIII 250 IU/von Willebrand factor 500 IU complex, Powder for injection (50 IU/mL FVIII).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL New Zealand Hizentra NZ Human Normal Immunoglobulin (20%) solution for subcutaneous injection.
-
Prescription medicine decision summaryHemgenix (etranacogene dezaparvovec) has been approved for the treatment of adults with haemophilia B (congenital factor IX deficiency).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL New Zealand Privigen NZ normal immunoglobulin (human) 100 g/L, 10% solution for intravenous infusion.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Malaysia Aleviate Human Coagulation Factor VIII 500IU/von Willebrand factor 1200IU complex, Powder for injection (50IU/mL FVIII).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Malaysia Aleviate Human Coagulation Factor VIII 250IU/von Willebrand factor 600IU complex, Powder for injection (50IU/mL FVIII).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Hong Kong Biostate Human Coagulation Factor VIII 250IU/von Willebrand factor 500IU complex, Powder for injection (50IU/mL FVIII).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Malaysia Biostate® Human Coagulation Factor VIII 250 IU/von Willebrand Factor 500 IU powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Malaysia Biostate® Human Coagulation Factor VIII 500 IU/von Willebrand Factor 1000 IU powder for injection vial.